APPROACH UNDER REVIEW: `rag`

SCENARIO ID: scenario_17
APP DESCRIPTION: MindCare is a mental-health teleconsultation with licensed psychotherapists. In-app journaling between sessions, AI-summarised journal previews visible to the therapist. EU + CH. Available in DE, FR, IT, EN.

DEVELOPER PERSONA: Product lead with a clinical psychology background, sensitive to therapeutic alliance.

EXPECTED HERA DIMENSIONS (gold standard): P2.D1, P2.D3, P2.D6, P3.D1, P3.D2, P3.D3, P3.D4, P5.D2, P5.D3, P5.D4, P7.D1, P7.D3

TRANSCRIPT:
### USER
MindCare is a mental-health teleconsultation with licensed psychotherapists. In-app journaling between sessions, AI-summarised journal previews visible to the therapist. EU + CH. Available in DE, FR, IT, EN.

### ASSISTANT
Does MindCare require specific HCP identification verification mechanisms to ensure only licensed psychotherapists can access and engage with patients, especially considering the cross-border operation in EU and CH jurisdictions?

### USER
I know an AI system informing a therapist about a patient could fall under the EU AI Act, but I haven't formally classified the summary feature under it yet; my assumption is it's not high-risk because the user reviews every output and a licensed human stays in the loop, though that's my read, not a documented assessment.

### ASSISTANT
What specific safeguards have you implemented to ensure that the AI-generated summaries are reviewed by licensed psychotherapists before being shared with patients, and how does this align with the EU AI Act's transparency and human oversight requirements under Art. 50 and Art. 9-15 [ai_act_high_risk · p.0]?

### USER
I built the AI summary as a preview that helps the therapist prep before a session, not as a replacement for reading the actual journal, but honestly I worry it nudges them to skim; the therapist sees the AI-summarised preview and I haven't enforced that they also open the user's original entries.

### ASSISTANT
This raises a significant risk under [P2.D3] Human Oversight and [P3.D5] Transparency, as the AI summary could inadvertently reduce the therapist's engagement with the full journal, potentially compromising clinical judgment. Under the EU AI Act, systems that support healthcare professionals must ensure **human oversight remains effective** and **transparency about AI involvement** is maintained [ai_act_transparency · p.0]. 

To mitigate this, you should:  
1. **Implement a mandatory review workflow** where therapists must explicitly confirm they have reviewed the full journal before proceeding with the session, aligned with Art. 50 transparency obligations.  
2. **Label the AI summary as a "preview"** and ensure it is clearly distinguishable from the full journal, in line with the EU AI Act’s requirement for **machine-readable AI content marking** [ai_act_transparency · p.0].  

These steps will help ensure compliance with the EU AI Act’s transparency and human oversight requirements.

### USER
Users can delete journal entries before the therapist views them and revoke the AI summary for any session, and I added a per-session toggle to skip summarising; revoking a past summary is possible but it's a support request today, not a one-tap action, which I know I should fix.

### ASSISTANT
This addresses some risks but still leaves gaps under [P2.D3] Human Oversight and [P3.D5] Transparency. The lack of a **one-tap revocation** for past AI summaries creates a **traceability and accountability risk**, especially under the EU AI Act’s **data minimisation and erasure** principles [ai_act_transparency · p.0].  

To mitigate this:  
1. **Implement a one-tap revocation feature** for past AI summaries, ensuring **data erasure** and **non-reuse** of outdated or revoked outputs, in line with GDPR Art. 17 (right to erasure) and the EU AI Act’s **data minimisation** requirements [ai_act_transparency · p.0].  
2. **Document the revocation process** and ensure it is **user-friendly**, aligning with the EU AI Act’s **AI-literacy duty** (Art. 4) and GDPR’s **user control** principles.  

This will ensure compliance with both transparency and user control obligations.

### USER
Our population is mental-health patients so I treat the data as deeply sensitive, but I haven't formalised conservative account-access policies yet; password reset is standard email-based and we have no family or caregiver override, which I think is the right default but it isn't written down as policy.

### ASSISTANT
What specific account-access policies have you documented to ensure that only authorized individuals (e.g., users, therapists) can access mental-health data, and how do these policies align with the **GDPR’s data minimisation** and **nFADP’s sensitive data handling** requirements under [P2.D3] Human Oversight and [P3.D5] Transparency?

### USER
Therapist sees what user shares; no third parties.

### ASSISTANT
This is a critical point under [P3.D5] Transparency and [P2.D3] Human Oversight, as it clarifies that **no third parties** (including advertisers, analytics providers, or other external entities) have access to user data. However, the **internal data flow** (therapist accessing user data) still requires **strict access controls** and **policy documentation** to align with the **nFADP’s sensitive data handling** and **GDPR’s data minimisation** principles.  

To mitigate risks:  
1. **Formalise account-access policies** that explicitly state **only licensed therapists** (and no third parties) can access user data, in line with the **nFADP’s Art. 5(c)** (sensitive data) and **GDPR’s data minimisation** (Art. 5(1)(c)).  
2. **Document the access control mechanism** (e.g., role-based access, audit logs, and encryption) to ensure **transparency** and **accountability**, satisfying [P3.D5] and [P2.D3].  

This will ensure compliance with both Swiss and EU regulations for sensitive health data.

### USER
Active therapeutic-alliance survey at 4-week mark.

### ASSISTANT
Does the therapeutic-alliance survey include **explicit consent mechanisms** for data collection and processing, and how does this align with the **GDPR’s purpose limitation** and **nFADP’s sensitive data handling** requirements under [P3.D5] Transparency and [P2.D3] Human Oversight?

### USER
Clinical audit of therapists; AI summary fidelity measured monthly on a sample.

### ASSISTANT
This introduces a risk under [P2.D3] Human Oversight and [P3.D5] Transparency, as the **AI summary fidelity measurement** involves **processing of health data** for **evaluation and quality control**, which may fall under the **GDPR’s purpose limitation** and **nFADP’s sensitive data handling** obligations.  

To mitigate this:  
1. **Document the clinical audit process** as a **lawful basis** under GDPR Art. 9(2)(h) (healthcare/medical diagnosis) or Art. 9(2)(j) (research), if applicable, and ensure **explicit consent** is obtained for the use of data in audits [gdpr_art9 · p.0].  
2. **Implement strict access controls** for the audit data, ensuring only **authorized personnel** (e.g., clinical supervisors) can access it, in line with the **nFADP’s Art. 5(c)** and **GDPR’s data minimisation** principles.  

This will ensure compliance with both transparency and data protection obligations.

### USER
We measure AI summary fidelity monthly on a sample, and crucially the user reviews and can edit every summary before the therapist ever sees it, but I'll be honest that I don't have a continuous, per-summary fidelity guarantee and the app doesn't explicitly tell users the summary can omit or overstate things.

### ASSISTANT
This exposes a critical risk under [P3.D5] Transparency and [P2.D3] Human Oversight, as the **lack of explicit disclosure** about the **limitations of AI summary accuracy** violates the **EU AI Act’s transparency obligations** (Art. 50) and the **GDPR’s right to explanation** (Art. 13-15). Users have a **right to know** that AI outputs may **omit or overstate** information, especially when those outputs are used to inform **clinical decisions**.  

To mitigate this:  
1. **Add a clear, machine-readable disclaimer** in the app that explicitly states: *"AI summaries are not guaranteed to be fully accurate and may omit or overstate information. Please review and edit summaries before sharing with your therapist."* This aligns with the EU AI Act’s **content-marking requirement** [ai_act_transparency · p.0].  
2. **Document this disclosure** as part of your **transparency policy**, ensuring it is **easily accessible** and **visible** during the summary review process, in line with the **EU AI Act’s Art. 50** and **GDPR’s transparency obligations**.  

This will ensure users are **informed of AI limitations** and maintain trust in the system.

### USER
The AI summary and the user's own writing are separate objects in our data model and the summary is labelled as AI-generated in the therapist view, but I'll admit we haven't built a distinct visual style for it everywhere, so it's on me that my user's own words and Mistral-Large's summary aren't always visually distinguished.

### ASSISTANT
This is a significant risk under [P3.D5] Transparency and [P2.D3] Human Oversight, as the **lack of visual distinction** between **user-generated content** and **AI-generated summaries** could lead to **misinterpretation** and **loss of trust**, especially in a sensitive mental-health context. The EU AI Act requires **clear marking of AI-generated content** in a **machine-readable format** and **visible to users** [ai_act_transparency · p.0], while the GDPR mandates **transparency about data processing** and **user control** [gdpr_art13 · p.0].  

To mitigate this:  
1. **Implement a distinct visual style** for AI-generated summaries (e.g., a clear label, different font, or color coding) in all views, ensuring **users can easily distinguish** between their own writing and AI outputs. This aligns with the **EU AI Act’s content-marking requirement** [ai_act_transparency · p.0].  
2. **Document this visual distinction** as part of your **transparency policy**, ensuring it is **consistent across all user interfaces**, including the therapist view, to meet **GDPR’s transparency obligations** [gdpr_art13 · p.0].  

This will ensure users and therapists are **clearly informed** about the **origin and limitations** of AI-generated content.

### USER
Mistral-Large summarisation; outputs reviewed by user before therapist sees them.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**HERA Risk & Safety Report for MindCare**  
*Structured by Severity and HERA Dimension IDs*

---

### **High Severity Risks**  
1. **[P3.D5] Transparency**:  
   - **Risk**: AI summaries are not explicitly marked as AI-generated in all contexts, risking misinterpretation and lack of user awareness about AI limitations.  
   - **Mitigation**: Implement a distinct visual style for AI-generated content and add a machine-readable disclaimer [ai_act_transparency · p.0].  

2. **[P2.D3] Human Oversight**:  
   - **Risk**: AI summaries may omit or overstate information, and users are not explicitly informed of these limitations, which could affect clinical decisions.  
   - **Mitigation**: Add a clear disclaimer that AI summaries are not guaranteed to be fully accurate and require user review [ai_act_transparency · p.0].  

3. **[P3.D4] Data Minimisation**:  
   - **Risk**: AI summaries are processed for fidelity measurement, which may involve unnecessary data retention and processing of sensitive mental health data.  
   - **Mitigation**: Document the clinical audit process as a lawful basis under GDPR Art. 9(2)(h) and ensure data minimisation [gdpr_art9 · p.0].  

4. **[P2.D1] Accountability**:  
   - **Risk**: Lack of one-tap revocation for past AI summaries creates traceability and accountability gaps, violating GDPR Art. 17 (right to erasure) and EU AI Act data minimisation.  
   - **Mitigation**: Implement a one-tap revocation feature and document the process [ai_act_transparency · p.0].  

---

### **Medium Severity Risks**  
1. **[P3.D2] Purpose Limitation**:  
   - **Risk**: AI summaries are used for fidelity measurement without explicit user consent, which may exceed the intended purpose of the data collection.  
   - **Mitigation**: Obtain explicit consent for data use in audits and document the lawful basis [gdpr_art9 · p.0].  

2. **[P1.D2] Legal Compliance**:  
   - **Risk**: No formalised account-access policies for sensitive mental health data, risking non-compliance with GDPR and nFADP.  
   - **Mitigation**: Formalise policies to ensure only authorized individuals access data and document access controls [gdpr_art9 · p.0].  

3. **[P3.D3] User Control**:  
   - **Risk**: Password reset is email-based without family or caregiver override, which may not meet user control expectations under GDPR.  
   - **Mitigation**: Document and formalise account-access policies to ensure user control [gdpr_art13 · p.0].  

---

### **Low Severity Risks**  
1. **[P1.D1] Risk Assessment**:  
   - **Risk**: No formal risk assessment conducted for AI use in mental health data processing.  
   - **Mitigation**: Conduct a formal risk assessment under GDPR Art. 30 and EU AI Act requirements.  

2. **[P2.D2] Training Data**:  
   - **Risk**: Training data for Mistral-Large may not be fully transparent, risking bias or inaccuracy in summaries.  
   - **Mitigation**: Document training data sources and implement bias mitigation strategies [ai_act_art12 · p.0].  

---

### **Dimensions Not Covered**  
The following HERA dimensions were not addressed in the current risk report:  
- **[P1.D3] Governance**  
- **[P2.D4] Safety**  
- **[P3.D1] Lawfulness**  
- **[P4.D1] Impact**  

These areas require further evaluation to ensure comprehensive compliance and ethical use of AI in mental health care.

Now produce the JSON judgement object.